Abstract
Genital herpes is a sexually transmitted disease caused by herpes simplex virus type 2 (HSV-2) and, less often (about 15%), type 1 (HSV-1). Epidemiological studies indicate that HSV-1 is found predominantly in lesions of the lips, face and other nongenital sites, whereas HSV-2 is almost found always in the ano-genital area. The reported increase in HSV1 genital infections over the last few decades (now about 20–40%) may be due to changes in sexual practices. The mean age at primary infection is 20–24 years, type 2 infections occurring mainly after puberty.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Whitley RJ, Gnann JW Jr (1992) Acyclovir: a decade later. N J Engl Med 327: 782–789
Bryson Y et al (1982) Treatment of the first episode of genital herpes simplex infection with oral acyclovir, a randomized double-blind controlled trial in normal subjects. N Engl J Med 308: 916–920
Crumpacker CS, Gulick RM (1993) Herpes simplex. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freed-berg IM, Austen KF (eds) Dermatology in general medicine. Vol. II. McGraw-Hill, 2531–2543
Mertz GJ, Jones CC, Mills J et al (1988) Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection: a multicenter double-blind trial. JAMA 260: 201–206
Goldberg LH, Kaufman R, Kurtz T et al (1993) Long-term suppression of recurrent herpes with acyclovir. Arch Dermatol 129: 582–527
DeMiranda P, Blum MR (1983) Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 12 [Suppl B]: 29–37
Katsambas A (1994) Quality of life in Dermatology and the European Academy of Dermatology. J Eur Acad Dermatovener 3: 211–214
Lalezari JP, Drew WL, Glutzer E et al (1994) Treatment with intravenous (S)-1–13-hydroxy-2-(phosphonylmethoxy) propyl]-cytosine of acyclovi-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 170: 570–572
Snoeck R, Andrei G, Gerard M et al (1994) Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S) (3-hydroxy-2phosphonylmethoxypropyl) cytosine ( HP-MPC ). Clin Infect Dis 18: 570–578
Langenberg AG, Burke RL, Adair SF et al (1995) A recombinant glycoprotein vaccine for herpes simplex type 2: safety and efficacy. Ann Inter Med 122: 889–898
Burke RL, Goldbeck C, Ng P et al (1994) The influence of adjuvant on therapeutic efficacy of a recombinant genital herpes vaccine. Lancet 343: 1460–1463
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Teofoli, P., Puddu, P., Lotti, T.M. (2000). Herpes Simplex Genitalis. In: Katsambas, A.D., Lotti, T.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-03835-2_41
Download citation
DOI: https://doi.org/10.1007/978-3-662-03835-2_41
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-03837-6
Online ISBN: 978-3-662-03835-2
eBook Packages: Springer Book Archive